| THE REGENTS OF THE UNIVERSITY OF COLORADO Patent applications |
| Patent application number | Title | Published |
|---|
| 20120116504 | Reliably Retained Shape Memory Ophthalmological Implants - An implantable ophthalmological device ( | 05-10-2012 |
| 20120108492 | LIGAND-SPECIFIC NON-ANTIBODY COMPOUNDS THAT INHIBIT CR2 ACTIVATION AND METHODS OF USE THEREOF - The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof. | 05-03-2012 |
| 20120100301 | Nucleation of Ultrathin, Continuous, Conformal Metal Films Using Atomic Layer Deposition And Application As Fuel Cell Catalysts - A method to achieve a conformal ultrathin film of platinum or one of its alloys on a substrate that can be economically used as a heterogeneous catalyst, such as automotive polymer electrolyte membrane (PEM) fuel cell catalyst. The method includes using a hydrogen plasma in platinum atomic layer deposition along with tungsten as a substrate or anchoring adhesive layer to assist platinum nucleation and deposition. | 04-26-2012 |
| 20120071432 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS - The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS. | 03-22-2012 |
| 20120065709 | METHODS AND DEVICES FOR VISIBLE LIGHT MODULATION OF MITOCHONDRIAL FUNCTION IN HYPOXIA AND DISEASE - The present invention provides methods of using electromagnetic radiation in the visible portion of the spectrum to modulate mitochondrial function in the treatment of various conditions, including Alzheimer's disease, other demential, hypoxia and diabetic peripheral neuropathy, and sensory disorders of the extremities. | 03-15-2012 |
| 20120058091 | DIAGNOSTIC AND THERAPEUTIC TREATMENTS RELATED TO MITOCHONDRIAL DISORDERS - The invention is based in part on the discovery that chromosomal disorders such as Down Syndrome can be diagnosed by assessing maternal mitochondrial status. Thus the invention relates to diagnostic and therapeutic methods and related products for chromosomal disorders such as Downs Syndrome, for example, for identifying a risk of fetal Downs Syndrome and methods of mitigating that risk. The methods also are useful for other therapies where it is desirable to manipulate mitochondria such as tissue generation. | 03-08-2012 |
| 20120042588 | INTEGRATED PHOTOVOLTAIC MODULE - The disclosed embodiments increase the power generated by a photovoltaic (PV) array, when the PV panels within the PV array are not uniformly illuminated or oriented or when PV panels are mismatched (e.g., have varying performance characteristics) and/or operate at non-uniform temperatures. It also provides simpler interconnection and wiring of the elements (e.g., PV panels) of the array. A dc-dc converter comprised of a DC transformer is coupled to each PV panel in a photovoltaic array to generate an increased dc voltage from a lower dc voltage produced by the PV panel. The outputs of the dc-dc converters are connected in parallel to a dc bus, which distributes the resulting voltage. As a result, the energy generated by the PV array is increased, the costs of system design and installation are reduced, and it becomes feasible to install PV arrays in new locations such as on gabled or non-planar roofs. | 02-23-2012 |
| 20120040896 | COMPOSITIONS, METHODS AND USES FOR MODULATION OF BRCA 1 - Embodiments of the present invention generally relate to methods, compositions and uses for diagnosis and treatment of cancer. Certain embodiments report methods and compositions for diagnosing and/or treating a subject having a BRCA1-related cancer or sporadic cancer. Some embodiments disclose treatments that can include, but are not limited to, modulation of BRCA1. In some embodiments, methods for identifying a subject with unstable BRCA1 protein are reported. | 02-16-2012 |
| 20120022011 | HSP90 INHIBITORS WITH MODIFIED TOXICITY - The invention provides purified 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders. | 01-26-2012 |
| 20120015872 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
| 20120014952 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
| 20110318335 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES - Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies. The systems and methods of the invention may be used to treat drug-resistant or multi-drug resistant cancers. | 12-29-2011 |
| 20110286938 | NON-INVASIVE DETECTION OF COMPLEMENT-MEDIATED INFLAMMATION USING CR2-TARGETED NANOPARTICLES - Methods of non-invasive imaging of complement-mediated inflammation are provided. Compositions including CR-targeted ultrasmall superparamagnetic nanoparticles or aggregates thereof for use with those methods are also provided. | 11-24-2011 |
| 20110275926 | Susceptibility Weighted Magnetic Resonance Imaging Of Venous Vasculature - Methods, systems, and devices are described for substantially simultaneous acquisition of magnetic resonance angiography (MRA) and magnetic resonance venography (MRV) data. Some embodiments provide susceptibility weighted magnetic resonance imaging of vasculature, including generating a multi-echo pulse sequence having a repetition time, and a first echo and a second echo during the repetition time; acquiring MRA data from at least the first echo; and acquiring MRV data from at least the second echo. The MRA data and/or the MRV data may also be post-processed (e.g., filtered, displayed, etc.). Various embodiments provide additional functionality, including techniques for processing data from an unsampled portion of one echo using sampled data from another echo. | 11-10-2011 |
| 20110251229 | (+)-OPIOIDS AND METHODS OF USE - The invention provides 4,5-epoxymorphinan or a derivative thereof, a morphinan or a derivative thereof, or a pharmaceutical salt or a prodrug thereof. The present invention also provides compositions comprising the same, and methods for using the same. In particular, the invention relates to TLR antagonistic opioids and methods for using the same. | 10-13-2011 |
| 20110249866 | METHODS AND SYSTEMS FOR THREE DIMENSIONAL OPTICAL IMAGING, SENSING, PARTICLE LOCALIZATION AND MANIPULATION - Embodiments include methods, systems, and/or devices that may be used to image, obtain three-dimensional information from a scence, and/or locate multiple small particles and/or objects in three dimensions. A point spread function (PSF) with a predefined three dimensional shape may be implemented to obtain high Fisher information in 3D. The PSF may be generated via a phase mask, an amplitude mask, a hologram, or a diffractive optical element. The small particles may be imaged using the 3D PSF. The images may be used to find the precise location of the object using an estimation algorithm such as maximum likelihood estimation (MLE), expectation maximization, or Bayesian methods, for example. Calibration measurements can be used to improve the theoretical model of the optical system. Fiduciary particles/targets can also be used to compensate for drift and other type of movement of the sample relative to the detector. | 10-13-2011 |
| 20110243996 | Spray freeze dry of compositions for intranasal administration - This invention provides methods and compositions to preserve bioactive materials, such as peptides, nucleic acids, viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for intranasal administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles for intranasal administration. | 10-06-2011 |
| 20110207156 | Biomarkers for Diagnosis of Breast Cancer - The present invention provides methods and kits for determining breast cancer. The invention includes the identification and use of biomarkers that are present in different amount or differentially expressed in breast cancer versus normal controls. | 08-25-2011 |
| 20110201962 | Statistical, Noninvasive Measurement of Intracranial Pressure - Tools and techniques for the rapid, continuous, invasive and/or noninvasive measurement, estimation, and/or prediction of a patient's intracranial pressure. In an aspect, some tools and techniques can predict the onset of conditions such as herniation and/or can recommend (and, in some cases, administer) a therapeutic treatment for the patient's condition. In another aspect, some techniques employ high speed software technology that enables active, long term learning from extremely large, continually changing datasets. In some cases, this technology utilizes feature extraction, state-of-the-art machine learning and/or statistical methods to autonomously build and apply relevant models in real-time. | 08-18-2011 |
| 20110160285 | IDENTIFICATION OF MIRNA PROFILES THAT ARE DIAGNOSTIC OF HYPERTROPHIC CARDIOMYOPATHY - Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy. For example, agents such as miRNA mimics, miRNA inhibitors or siRNAs for a given miRNA or gene can be used to modulate the level of these molecules thereby inhibiting or preventing hypertrophic cardiomyopathy. | 06-30-2011 |
| 20110135618 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF - The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site. | 06-09-2011 |
| 20110106044 | METHODS FOR EVALUATING THE AGGREGATION OF A PROTEIN IN A SUSPENSION INCLUDING ORGANOPOLYSILOXANE AND MEDICAL ARTICLES COATED WITH ORGANOPOLYSILOXANE CONTAINING A PROTEIN SOLUTION - This invention relates to methods for evaluating or inhibiting the aggregation of a protein in an aqueous suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution including sugar and a non-ionic surfactant. | 05-05-2011 |
| 20110044999 | IL-32 MODULATORS - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. | 02-24-2011 |
| 20110014270 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION INJURY AND RELATED CONDITIONS - Disclosed are Lipids, Annexin, and Lipid-Annexin Complexes for Use in the Prevention and/or Treatment of Ischemia-Reperfusion injury and reperfusion injury associated with a variety of diseases and conditions. Also disclosed are therapeutic targets and compositions for the prevention and treatment of ischemia-reperfusion injury and diseases and conditions associated with ischemia-reperfusion injury. | 01-20-2011 |
| 20110014173 | AXL TYROSINE KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME - Disclosed are novel inhibitors of the AxI receptor tyrosine kinase (RTK) and methods of using such inhibitors in a variety of therapeutic approaches in the areas of cancer therapy and anti-thrombosis (anti-clotting) therapy. | 01-20-2011 |
| 20100304338 | POLYMER IMPRESSION MATERIALS - This invention relates to methods and compositions for single component photoinitiated dental impression materials. The impression material is workable in its pre-cured state, cures rapidly upon exposure to light, and exhibits desirable processing conditions such as short setting time, long working time, no void formation, good wettability, mechanical properties, and detail reproduction. | 12-02-2010 |
| 20100291357 | HYDROGELS AND METHODS FOR PRODUCING AND USING THE SAME - The present invention relates to hydrogels and methods for producing and using the same. In particular, some embodiments of the invention relate to hydrogels and methods for patterning the same. | 11-18-2010 |
| 20100278400 | THREE-DIMENSIONAL SINGLE-MOLECULE FLUORESCENCE IMAGING BEYOND THE DIFFRACTION LIMIT USING A DOUBLE-HELIX POINT SPREAD FUNCTION - Embodiments of the present invention can resolve molecules beyond the optical diffraction limit in three dimensions. A double-helix point spread function can be used to in conjunction with a microscope to provide dual-lobed images of a molecule. Based on the rotation of the dual-lobed image, the axial position of the molecule can be estimated or determined. In some embodiments, the angular rotation of the dual-lobed imaged can be determined using a centroid fit calculation or by finding the midpoints of the centers of the two lobes. Regardless of the technique, the correspondence between the rotation and axial position can be utilized. A double-helix point spread function can also be used to determine the lateral positions of molecules and hence their three-dimensional location. | 11-04-2010 |
| 20100249763 | Laser Tissue Fusion of Septal Membranes - A laser tissue fusion device is optimized for particular surgical applications to join tissue layers. The device has two opposed arms that engage and disengage to clamp and release layers of tissue therebetween. The distal end of the first arm is disposed opposite the distal end of the second arm. A laser energy source generates therapeutic laser energy is either integrated within the device is a separate unit. An energy pathway transmits the laser energy to the distal end of the first arm to deliver the laser energy to tissue layers clamped between the distal ends of the arms. An actuator decreases the separation distance between the distal ends of the arms to clamp the tissue layers and activates the laser energy source upon engagement. The laser energy source delivers a burst of energy at a predetermined wavelength for a predetermined period of time sufficient to spot weld the tissue. | 09-30-2010 |
| 20100240665 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell expresses certain sensitivity or resistance biomarkers, or genomic classifiers. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate this methodology are also provided. | 09-23-2010 |
| 20100239523 | TLR MODULATORS AND METHODS FOR USING THE SAME - The invention provides Toll-like receptor (TLR) modulators, compositions comprising the same, and methods for using the same. | 09-23-2010 |
| 20100207016 | Channel Cell System - A cold-atom system has multiple vacuum chambers. One vacuum chamber includes an atom source. A fluidic connection is provided between that vacuum chamber and another vacuum chamber. The fluidic connection includes a microchannel formed as a groove in a substantially flat surface and covered by a layer of material. | 08-19-2010 |
| 20100200739 | Ultracold-Matter Systems - Cold-atom systems and methods of handling cold atoms are disclosed. A cold-atom system has multiple chambers and a fluidic connection between two of the chambers. One of these two chambers includes an atom source and the other includes an atom chip. | 08-12-2010 |
| 20100184710 | Therapeutic Bifunctional Compounds - The invention generally relates to systems and methods for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using a bifunctional compound that inhibits both fatty acid metabolism and glycolysis. Thus, the invention links a fatty acid metabolism inhibitor to a glycolysis inhibitor. More particularly, the invention provides novel bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a glucose derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of 2-deoxy-D-glucose. | 07-22-2010 |
| 20100166789 | PROTEINS FOR USE IN DIAGNOSING AND TREATING INFECTION AND DISEASE - The present invention describes compositions of thymus derived peptides and uses therefore in diagnostic methods and for the treatment of diseases associated with reduced T helper cell counts, diseases such as infection, e.g., HIV infection and other viral infections, parasitic, and bacterial infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, rheumatoid arthritis, Alzheimer's disease, asthma, allergy, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease/irritable bowel syndrome, Crohn's disease, Psoriasis, Chronic obstructive pulmonary disease, Systemic lupus erythematosus, transplant rejection and cancer. | 07-01-2010 |
| 20100166725 | Human Cystathionine beta-Synthase Variants and Methods of Production Thereof - Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described. | 07-01-2010 |
| 20100056993 | Medical Systems and Methods of Use - This invention provides ambulatory medical systems that include a monitoring device, a therapeutic substance administering device, and a receiver-controller for receiving a signal generated by the monitoring device and controlling the therapeutic substance administering device based on the information received from the monitoring device. The invention also provides methods for using the same. | 03-04-2010 |
| 20100014740 | OPTIMAL ROTATIONAL TRAJECTORY DETERMINATION FOR RA BASED ON PRE-DETERMINED OPTIMAL VIEW MAP - It is described a method for determining an optimal trajectory ( | 01-21-2010 |
| 20090304741 | Yeast-Dendritic Cell Vaccines and Uses Thereof - Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed. | 12-10-2009 |
| 20090291872 | Ionic Liquids and Methods For Using the Same - The present invention provides compositions comprising ionic liquids and an amine compound, and methods for using and producing the same. In some embodiments, the compositions of the invention are useful in reducing the amount of impurities in a fluid medium or a solid substrate. | 11-26-2009 |
| 20090269739 | Kit for detection of telomerase reverse transcriptase nucleic acids - The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers. | 10-29-2009 |
| 20090258064 | COMPOSITIONS OF UCP INHIBITORS, FAS ANTIBODY, A FATTY ACID METABOLISM INHIBITOR AND/OR A GLUCOSE METABOLISM INHIBITOR - Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers. | 10-15-2009 |
| 20090258027 | Methods of modulating immune function - The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject. | 10-15-2009 |
| 20090248141 | Shape Memory Polymer Medical Devices - Medical devices for in vivo medical applications are disclosed. The medical devices are constructed of shape memory polymer (SMP) materials capable of assuming a memory shape at physiological temperatures. These medical devices may be used in surgical procedures and in both vascular and non-vascular applications. These SMP medical devices have a post-implantation memory shape that is substantially identical to or slightly larger than the insertion site to adapt to vessel growth or size changes. SMP medical devices may be formed as stents or occlusion devices (i.e., plugs) having a number of different structural features. The SMP medical devices may be formed from a first monomer and a second cross-linking monomer, wherein the weight percentages of the first and second monomers are selected by performing an iterative function to reach a predetermined glass transition temperature (T | 10-01-2009 |
| 20090232799 | Antibodies that bind urokinase-type plasminogen activator and epitopes therefor - Anti-uPA antibodies and antigen-binding regions thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding regions, are described. Also described are methods of using such antibodies and antigen-binding regions to bind uPA epitopes and activate uPA function, such as inhibition of uPA mediated inflammation. Epitopes that can be used to activate uPA function and anti-inflammation activity are also described, as well as methods of identifying compounds that can bind them. | 09-17-2009 |
| 20090221956 | MULTI-PARAMETER MONITORING DEVICE FOR USE WITH CENTRAL AND INTRAVENOUS ADMINISTRATION OF MEDICATION - The invention generally relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being centrally administered in connection with treatment of a CNS-related condition or disorder, e.g., a neuro-psychiatric disorder. In another aspect, the invention relates to a multi-parameter monitoring device for in-line use to monitor a therapeutic agent solution passing therethrough prior to being (a) intravenously administered to a patient in connection with a treatment, such as is the case where the therapeutic agent solution comprises an IV administerable solution, or (b) administered to a patient in connection with a treatment for diabetes, such as is the case where the therapeutic agent comprises insulin. | 09-03-2009 |
| 20090220535 | THERAPEUTIC AND PROPHYLACTIC VACCINE FOR THE TREATMENT AND PREVENTION OF PAPILLOMAVIRUS INFECTION - Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed. | 09-03-2009 |
| 20090218519 | Three-Dimensional Direct-Write Lithography - A method of creating a region of index change in a photopolymer includes providing a photopolymer having a photosensitivity to light of a particular wavelength and creating a region of index change in the photopolymer by applying direct write lithography to expose the photopolymer of the region to light that includes the particular wavelength. | 09-03-2009 |
| 20090209480 | CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS - The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS. | 08-20-2009 |
| 20090175836 | PRELAMIN A PRE PEPTIDE AS A UNIVERSAL STEM CELL DIFFERENTIATION SIGNAL - Disclosed is the use of prelamin A pre peptide and homologues or analogs thereof for the induction of cell differentiation and tissue or organ growth and repair processes. The invention extends to virtually any cell, including both embryonic and non-embryonic stem cells, such as stem cells that are progenitors for a wide variety of cell and tissue types. Also disclosed is the use of prelamin A pre peptide and prelamin A to determine and establish cell morphology and tissue architecture. Treatment of a variety of diseases and conditions, as well as cosmetic, general health, and anti-aging applications are described. | 07-09-2009 |
| 20090171098 | Heteroaryl Salts and Methods For Producing and Using the Same - The invention provides heteroaryl salts and methods for producing the same. In particular, the invention provides heteroaryl salts of the formula: | 07-02-2009 |
| 20090142367 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 06-04-2009 |
| 20090142366 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 06-04-2009 |
| 20090136453 | Methods for treating pain - Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions. | 05-28-2009 |
| 20090131367 | Combinations of HDAC Inhibitors and Proteasome Inhibitors - Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of cancer. | 05-21-2009 |
| 20090088454 | ANTI-CANCER COMPOUNDS - The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers. | 04-02-2009 |
| 20090068227 | Use of neurotoxin therapy for treatment of urologic and related disorders - The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 03-12-2009 |
| 20090066382 | Digital Pulse-Width-Modulator with Discretely Adjustable Delay Line - A hybrid digital pulse width modulator (DPWM) with digital delay-locked loops (DLLs) is provided. In this implementation, the digital pulse-width-modulator is synthesizable and includes a digital delay-locked loop around a delay-line to achieve constant frequency clocked operation. In this implementation, the resolution of the modulator is consistent over a wide range of process or temperature variations. The DPWM may implement trailing-edge, leading-edge, triangular, or phase-shift modulation. In an implementation suitable for DC-DC converters with synchronous rectifiers, for example, the DPWM may include two or more outputs for programmable dead-times. In another implementation, a digital pulse-width-modulator with a digital phase-locked loop is also provided. | 03-12-2009 |
| 20090061527 | Methods and Devices for Detecting Nucleic Acid Hybridization - The present invention provides novel methods and devices for detecting hybridization of nucleic acids using liquid crystals and cationic surfactants. | 03-05-2009 |
| 20090055627 | Efficient Pipeline Parallelism Using Frame Shared Memory - A systems and methods are disclosed that provide an efficient parallel pipeline for data processing using a multi-core processor. Embodiments allocate a shared memory portion of the memory that is accessible from more than one context of execution and/or process a frame in a plurality of processing stages processed by a context of execution. In some embodiments, each of the plurality of processing stages may be bound to a processing core of the multi-core processor. In other embodiments include one or more processing stages with a point-to-point communication mechanism that operates in shared memory. | 02-26-2009 |
| 20090047745 | BULK NEGATIVE INDEX OF REFRACTION MATERIALS WITH RESPONSE IN THE VISIBLE - Bulk negative refractive index materials (NIM) or left-handed metamaterials (LHM) as an amorphous and isotropic solid material consisting of mutually electrically insulated synthetic rings or pucks smaller than the wavelength of visible light. Each ring or puck contains a nanometer sized metallized nucleic acid ring containing one or more non-metallized segments. The bulk material can be formed as a plurality of individual pucks randomly oriented, or as multiple rings stacked together in an axial direction whose axes may be randomly oriented. | 02-19-2009 |
| 20090028974 | Use of Botulinum Toxin Therapy for Treatment of Recalcitrant Voiding Dysfunction - The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 01-29-2009 |
| 20090005300 | Antimicrobial Peptides and Methods of Use - Disclosed herein are novel antimicrobial peptides with useful, improved, or superior properties such as antimicrobial activity, desirable levels of hemolytic activity, and therapeutic index against a broad range of microorganisms including gram-negative and gram-positive bacteria and other organisms having a cellular or structural component of a lipid bilayer membrane. Also provided are methods of making and using such peptides to control microbial growth and in pharmaceutical compositions for treatment or prevention of infections caused by such microorganisms. Certain peptides are disclosed utilizing a structure-based rational design relating to an antimicrobial peptide, V | 01-01-2009 |
| 20090004312 | Use of Neurotoxin Therapy for Treatment of Urologic and Related Disorders - The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | 01-01-2009 |
| 20080318188 | Dimer Acid-Derived Dimethacrylates and Use in Dental Restorative Compositions - The present invention provides polymerizable dental compositions comprising a dimer acid-derived monomer such as a dimer acid-derived di(meth)acrylate monomer. In one embodiment, the dimer acid-derived monomer is of the formula (I): wherein R | 12-25-2008 |
| 20080310201 | Digital Power Factor Correction - A digital PFC (DPFC) control approach that requires no input voltage sensing or current loop compensation is described. The approach can provide stable, low-harmonic operation over a universal input voltage range and load ranging from high-load operation in continuous conduction mode down to near-zero load. A fast voltage loop can also be incorporated into a DPFC controller to provide additional control of the power stage. A controller can be based on low-resolution DPWM and A/D converters, can be implemented without microcontroller or DSP programming, and is well suited for simple, low-cost integrated-circuit realizations. | 12-18-2008 |
| 20080310200 | MULTI-PHASE MODULATOR - An architecture is described for digital multi-phase modulators (MPM) that leads to an efficient, high performance hardware realization. The combined modulator, switching phases and output filter can be viewed as a multi-level digital to analog converter with high power output, or a power D/A, and concepts used in D/A converters are leveraged to achieve high performance and hardware efficiency. The modulator can be split into three functional blocks including a decoder that determines how many phases are on at any time, a selector that determines which phases are on at any time, and a single high resolution module that is time shared among all phases. The resulting architecture scales favorably with a large number of phases, f | 12-18-2008 |
| 20080290287 | Multichannel Energy Analyzer for Charged Particles - The present invention provides charged particle energy deflectors, analyzers, devices, device components and methods for terminating charged particle systems and electrically isolating device components. One embodiment of the present invention provides a transparent field termination system for a cylindrical charged particle deflector that is capable of providing an electric field that closely approximates the substantially logarithmically varying electric field of the deflector. The present invention also provides multichannel charged particle analyzers and multichannel EEL spectrometers capable of measuring charged particle energy distributions, including electron energy distributions, with enhanced resolution and sensitivity compared to conventional analyzers. | 11-27-2008 |
| 20080276056 | Efficient Point-To-Point Enqueue And Dequeue Communications - Systems and methods for writing and/or reading data to a point-to-point shared memory communication mechanism are provided according to embodiments disclosed herein. According to one embodiment, a determination may be made whether a first memory location in the cache of a general purpose multi-core processor includes an empty symbol. If the first memory location includes the empty symbol, then data may be placed in the first memory location in the cache. If the first memory location does not include the empty symbol, then waiting until it does. In another embodiment, a determination may be made whether a first memory location of a general purpose multi-core processor includes the empty symbol. If it does not, then data may be read from the first memory location and/or the empty symbol may be written into the first memory location. If the first memory location does include the empty symbol, then pausing. | 11-06-2008 |
| 20080267975 | Mer Diagnostic and Therapeutic Agents - Mer diagnostic and therapeutic agents are disclosed. The agents are useful in the diagnosis and treatment of a variety of diseases including leukemia, lymphoma, and clotting disorders. | 10-30-2008 |
| 20080267908 | Il-32 Modulators - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. Proteinase 3 has been identified as an IL-32 binding protein capable of deavege thereof. Inhibition of PR 3 activity to process IL-32 or neutralization of IL-32 by-inactive PR3 or its fragments may reduce the consequences of IL-32 in immune regulated diseases (e.g. inflammatory diseases). | 10-30-2008 |
| 20080235382 | FAULT TOLERANT TCP SPLICE SYSTEMS AND METHODS - Computer architecture and method splice a new TCP connection. A proxy group for the new TCP connection is determined and, at one of the proxies, the new TCP connection is accepted. At the one proxy, a client request is received from a client of the new TCP connection and an appropriate backend server to handle the client request is determined. At the one proxy, the client request is spliced and sent to the appropriate backend server. Splicing state information of the new TCP connection is sent from the one proxy to other proxies of the proxy group. Each subsequent TCP segment of the new TCP connection is spliced and sent to the appropriate backend server at any one proxy of the proxy group. | 09-25-2008 |
| 20080234265 | Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors - Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer. | 09-25-2008 |
| 20080228186 | Graft Fixation Device - In one aspect a device is disclosed for use as a bone implant comprising, a body having a pre-implantation shape and a post-implantation shape different from the pre-implantation shape. The body is configured to change from the pre-implantation shape to the post-implantation shape in response to the body being activated. The body is configured to be inserted in a bone recess while the body is in the pre-implantation shape. In another aspect a method is disclosed comprising inserting a cable member into a recess in a bone, inserting a retention device into the recess, the retention device containing a shape memory material, and activating the shape memory material. | 09-18-2008 |
| 20080214666 | Products and Methods Related to Mono-Methyl Branched-Chain Fatty Acids - Disclosed are genes and proteins related to the biosynthesis and function of mono-methyl branched-chain fatty acids (mmBCFA) in eukaryotes, as well as the functions of mmBCFA in eukaryotic organisms. Also disclosed are methods to regulate the biosynthesis and function of mmBCFA in an organism, methods to use the valuable targets associated with mmBCFA biosynthesis and function as therapeutic agents and to screen for pharmaceuticals and nutraceuticals, or to investigate or screen for regulators of metabolism, growth, development, and reproduction in eukaryotes. The present invention also includes highly specific and useful animal models for mmBCFA biosynthesis and function that can be used to explore pharmaceutical applications of the mmBCFA-involved biological processes. | 09-04-2008 |
| 20080202312 | SYSTEMS AND METHODS FOR DRIVING MULTIPLE SOLID-STATE LIGHT SOURCES - The present disclosure may relate generally to controlling multiple light sources and to systems and methods for reducing inefficiencies and interference in a light emitting diode (LED)-based backlighting systems for LCD televisions. | 08-28-2008 |
